Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Company Description (as filed with the SEC)
We are a clinical stage biopharmaceutical company focused on the development and commercialization of a clinical candidate, OCR-002, for the treatment of hepatic encephalopathy, or HE. HE is a serious complication of liver failure marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and, in its more severe form, stupor, coma and even death. Common causes of liver malfunction leading to HE include alcoholism and hepatitis as well as obesity, Type II diabetes, and acetaminophen overdose. OCR-002 is a novel molecule, ornithine phenylacetate, which functions as an ammonia scavenger. OCR-002 has been shown to lower ammonia in patients with cirrhosis when administered as a continuous intravenous infusion. ... More ...
Where does OCRX fit in the risk graph?
|Annual EPS Est:||$-1.97|
|Quarterly EPS Est:||-0.38|